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Artur Plonowski 3, Christopher J. Larson 3, Klaus Ley 2, Pedro Cabrales 4, Joseph L. Witztum 1,
Jerrold M. Olefsky 1,**, Yun Sok Lee 1,*ABSTRACT
Objective: Atherosclerosis is a major cause of cardiovascular disease. Monocyte-endothelial cell interactions are partly mediated by expression
of monocyte CX3CR1 and endothelial cell fractalkine (CX3CL1). Interrupting the interaction between this ligandereceptor pair should reduce
monocyte binding to the endothelial wall and reduce atherosclerosis. We sought to reduce atherosclerosis by preventing monocyte-endothelial
cell interactions through use of a long-acting CX3CR1 agonist.
Methods: In this study, the chemokine domain of CX3CL1 was fused to the mouse Fc region to generate a long-acting soluble form of CX3CL1
suitable for chronic studies. CX3CL1-Fc or saline was injected twice a week (30 mg/kg) for 4 months into Ldlr knockout (KO) mice on an
atherogenic western diet.
Results: CX3CL1-Fc-treated Ldlr KO mice showed decreased en face aortic lesion surface area and reduced aortic root lesion size with
decreased necrotic core area. Flow cytometry analyses of CX3CL1-Fc-treated aortic wall cell digests revealed a decrease in M1-like polarized
macrophages and T cells. Moreover, CX3CL1-Fc administration reduced diet-induced atherosclerosis after switching from an atherogenic to a
normal chow diet. In vitro monocyte adhesion studies revealed that CX3CL1-Fc treatment caused fewer monocytes to adhere to a human
umbilical vein endothelial cell monolayer. Furthermore, a dorsal window chamber model demonstrated that CX3CL1-Fc treatment decreased
in vivo leukocyte adhesion and rolling in live capillaries after short-term ischemia-reperfusion.
Conclusion: These results indicate that CX3CL1-Fc can inhibit monocyte/endothelial cell adhesion as well as reduce atherosclerosis.
 2018 The Authors. Published by Elsevier GmbH. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Cardiovascular disease (CVD) accounted for an estimated 31.5% of
global deaths in 2013 [1]. While all the multifactorial mechanisms
underlying atherosclerosis are not fully known, strong associations
with hypercholesterolemia [2], obesity [3], type 2 diabetes (T2DM) [4],
and insulin resistance [5] have been shown.
The development of atherosclerotic plaques involves enhanced LDL
trapping in the intima and formation of oxidized LDL, which leads to a
series of processes including adhesion of monocytes to the endothe-
lium, macrophage infiltration, cytokine release, and foam cell forma-
tion [6]. Thus, macrophage accumulation during atherosclerosis
progression contributes to inflammatory gene expression, foam cell
accumulation, smooth muscle cell modulation, and endothelial wall
thickening [7]. Recruitment of monocytes to the endothelium is a key
step in the development of atherosclerosis, and targeting this step can
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Both monocyte subsets are recruited to atherosclerotic vessels, but the
majority are Lys6Chi [9]. Once in the inflamed vessel, these monocytes
can differentiate to M1-like macrophages that take up lipid and
become foam cells [10]. Endothelial cells also play a critical role in
atherosclerosis, whereby pro-inflammatory conditions (e.g. high fat/
high cholesterol diet) promote leukocyte adhesion [11].
Fractalkine (CX3CL1) and its cognate receptor CX3CR1 are important
for immune cell trafficking [12]. CX3CL1 is expressed as a membrane-
bound protein (mCX3CL1), and the extracellular domain can be cleaved
and released into the circulation for actions at distal sites [13]. During
atherosclerosis, blood monocytes expressing CX3CR1 bind to blood
vessel endothelial cells-expressing mCX3CL1, promoting monocyte
adhesion [14]. The clustering of CX3CR1 receptors on the cell surface
further promotes adhesiveness between monocytes and endothelial
cells [15]. Several studies demonstrate that genetic deletion of either
CX3CL1 or CX3CR1 protects mice against atherosclerosis [16e18]. Inia, San Diego, La Jolla, CA, USA 2Division of Inflammation Biology, La Jolla Institute
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Abbreviations
CVD Cardiovascular disease
DWCM Dorsal window chamber model
FCD Functional capillary density
CX3CL1 Fractalkine
CX3CL1-Fc Fractalkine Fc fusion protein
HCD High cholesterol (1%)/low fat (4.4%) diet
Hct Hematocrit
HUVEC Human umbilical vein endothelial cells
HR Heart rate
i.p. Intraperitoneal
KO Knockout
LDL Low-density lipoprotein
LDLR Low-density lipoprotein receptor
MAP Mean arterial blood pressure
mCX3CL1 Membrane-bound fractalkine
NCD Normal chow diet
T2DM Type 2 Diabetes Mellitus
VEH Vehicle or saline treatment
WD Western diet
Original Articleaddition, subjects carrying a loss of function CX3CR1 M280 variant
show protection against atherosclerosis [19]. Collectively, these
studies suggest that interfering with monocyte CX3CR1 and endothelial
cell mCX3CL1 may be protective against atherosclerosis.
On the other hand, CX3CR1 KO mice demonstrate exaggerated hepatic
inflammation and fibrosis when they are experimentally induced
through CCl4 administration or bile duct ligation [20,21]. Moreover,
CX3CR1 KO mice exhibit impaired glucose tolerance with decreased
beta cell insulin secretion, whereas administration of a long acting
CX3CL1, tethered to the mouse Fc fragment (CX3CL1-Fc), improved
insulin secretion, insulin sensitivity, and glucose tolerance [22]. These
results indicate that soluble CX3CL1 administration exerts beneficial
effects on metabolic health. However, since genetic loss of CX3CR1 or
CX3CL1 is atheroprotective, one could raise a safety concern that a
soluble CX3CL1-Fc agonist might promote atherosclerosis.
In the current studies, we propose the opposite, hypothesizing that
soluble CX3CL1-Fc can act as an agonist against CX3CR1, disrupting
the interaction between monocytes and endothelial cells mediated by
endogenous mCX3CL1 and CX3CR1. To address this hypothesis, we
adopted in vitro and in vivo model systems that assess monocyte-
endothelial cell interactions in stressed conditions. We also tested
the effect of chronic CX3CL1-Fc administration on atherosclerosis
prevention, treatment, and after diet switch. We find that CX3CL1-Fc
decreases monocyte adhesion to the endothelium both in vitro and
in vivo. Moreover, we also demonstrate that CX3CL1-Fc treatment
reduced atherosclerosis throughout the aorta and aortic root in hy-
percholesterolemic Ldlr KO mice without changes in plasma choles-
terol levels. These beneficial changes were associated with reduced
aortic M1-like macrophages and T cells.
2. MATERIAL AND METHODS
2.1. Experimental mouse model
Eight week-old male C57BL/6 WT and ten week-old male Ldlr KO mice
on the C57BL/6 background were obtained from Jackson Labs (cat-
alog# 002207). CX3CL1-Fc was produced in collaboration with Takeda
California, Inc.90 MOLECULAR METABOLISM 20 (2019) 89e101  2018 The Authors. Published by Elsevier GmbH. Ta) Prevention Study: Ldlr KO mice were fed either a high cholesterol
(1%)/low fat (4.4%) diet (Envigo, catalog# TD.97131) or a high
cholesterol (1.25%)/high fat (40%) WD (Envigo, catalog# TD.02028)
and randomized to be injected with either CX3CL1-Fc (30 mg/kg) or
saline (VEH) intraperitoneally twice a week for 4 months. This dosing
regimen is slightly modified from our previous studies demon-
strating the anti-diabetic effects of CX3CL1-Fc [13].
b) Treatment Study: Ldlr KO mice were fed a high cholesterol/high fat
diet (Research Diets, catalog# D12108C) for 8 months. At 4 months,
a group of mice were sacrificed for baseline measurements and the
remaining were randomly split into two groups, one injected
intraperitoneally with CX3CL1-Fc (30 mg/kg) and the other with
saline (VEH) twice a week for the remaining 4 months.
c) Reversion Study: Ldlr KO mice were fed a high cholesterol/high fat
diet (Research Diets, catalog# D12108C) for 4 months and a group
of mice were sacrificed for baseline measurements. The remaining
mice were switched to a normal chow diet (NCD) and split into two
groups, one injected intraperitoneally with CX3CL1-Fc (30 mg/kg)
and the other with saline (VEH) twice a week and were sacrificed at
4 and 8 months after treatment began.
Mouse tissues collected and processed as detailed below.
2.2. Flow cytometry
a) Endotheliums: Aortas/carotids were collected from Ldlr KO mice
after their respective treatment regimen. Following euthanasia and
heparin perfusion, tissues were cut up and placed in a tube con-
taining a digestion cocktail of 450 U/mL Collagenase I, 250 UmL
Collagenase XI, 120 U/mL Hyaluronidase, and 120 U/mL DNase I.
These tubes were placed in a shaking incubator at 150 rpm and
37 C for 60 min. Following digestion, the digestion cocktail was
passed through a 70 mm filter into a fresh 15 ml conical tube, and
then centrifuged at 500 g and 4 C for 5 min.
b) Other Tissues: Spleens, blood, bone marrow, cervical lymph nodes,
axillary lymph nodes, mesenteric lymph nodes, and paraaortic
lymph nodes were collected from Ldlr KO mice after their respective
treatment regimen. After euthanasia and heparin perfusion, spleens
and lymph nodes were pushed through 70 mm filters into conical
tubes, and filters were washed with PBS. Tubes were centrifuged
for 5 min at 4 C and 500 g.
After aspirating supernatant and resuspending pellets, cells were
incubated with Zombie Red Viability Dye (Biolegend, catalog# 423110)
for 30 min at 4 C, then washed. Single cell suspensions were then
incubated with mouse FcR blocking reagent (Miltenyi Biotec, catalog#
130-092-575), and the following extracellular antibodies for 30 min at
4 C: AlexaFluor700-conjugated anti-CD45 (Biolegend, catalog#
103128), APC-eFluor780-conjugated anti-TCR-b (eBioscience, cata-
log# 47-5961-82) or PerCP-Cy5.5-conjugated anti-CD3 (Biolegend,
catalog# 100218), PerCP-conjugated anti-CD4 (Biolegend, catalog#
100538), BV421-conjugated anti-CX3CR1 (Biolegend, catalog#
149023), PE-Cy7-conjugated anti-CD69 (Biolegend, catalog# 104512),
APC-conjugated anti-CD103 (Biolegend, catalog# 121414), BV711-
conjugated anti-CD11b (Biolegend, catalog# 101242), FITC-
conjugated anti-CD64 (Biolegend, catalog# 139316), BV605-
conjugated anti-CD8a (Biolegend, catalog# 100744), BV510-
conjugated anti-CD86 (Biolegend, catalog# 105040), and PE-
conjugated anti-CD206 (Biolegend, catalog# 141706). Following in-
cubation, cells were washed, and then fixed according to the eBio-
science fixation buffer protocol. Data were acquired on the BD LSRIIhis is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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cytometer using FACSDiva software, and raw data were analyzed
using FlowJo software.
For analysis of monocyte development, single cell suspensions of bone
marrow or spleen were stained with live/dead fixable aqua cell stain kit
(ThermoFisher, catalog# L34957) and then the following antibodies:
APC-conjugated anti-Gr-1 (Biolegend, catalog# 108411), PerCP5.5-
conjugated CD45 (Biolegend, catalog# 103131), PE-conjugated Ly-
6C (Biolegend, catalog# 128007), FITC-conjugated CD11b (Biolegend,
catalog# 101205) and PE/Cy7-conjugated F4/80 (Biolegend, catalog#
123113). Following incubation, cells were washed, and then fixed
according to the eBioscience fixation buffer protocol. Data were ac-
quired on the BD Canto (RUO Orange) and then analyzed using Flowjo
software.
2.3. En face and aortic root analyses
At specified time points, Ldlr KO mice on their respective diet regimen
and treated  CX3CL1-Fc were euthanized by a lethal dose of
pentobarbital, and the circulation was perfused with isotonic EDTA-
PBS solution. This was followed by in situ fixation at physiological
pressure with formal sucrose (4% paraformaldehyde). Aortas were
then dissected, opened longitudinally, thoroughly cleansed of adven-
titial tissue, and stained with Sudan IV, as previously described [23].
Aortas were pinned out on a black wax pan (after adventitial removal),
and the percentage of atherosclerotic surface area was determined by
computer-assisted image analysis, as previously described in detail
[23].
At sacrifice, the heart and proximal aorta were obtained, embedded in
Optimal Cutting Temperature compound, and stored at 70 C. Aortic
root cross-sectional atherosclerosis was measured by cutting 10 mm
paraffin sections from the site where the first leaflet was seen until the
last leaflet. Sections at every 100 mm interval from the first leaflet were
stained with Oil Red O and hematoxylin. Quantitative analysis of lesion
and necrotic area was performed on each section with about 7e10
sections analyzed, spanning 1000 mm from the origin of the first visible
leaflet. The results are presented as total lesion or necrotic area in
mm2 of all aortic cross sections analyzed [24].
2.4. Plasma cholesterol/triglyceride assays and lipoprotein profiling
Plasma cholesterol was measured using a Cobas AutoAnalyzer with a
Cholesterol CHOD-PAP kit as per the manufacturer’s instructions
(Roche, catalog# 11,491,458-216). Plasma triglycerides were
measured with a Triglyceride eSL kit from Sekisui Diagnostics as per
their instructions (catalog# 236-60). Cholesterol and triglyceride lipo-
protein profiling was performed using fast performance liquid chro-
matography (FPLC) with a Superose 6 column as described previously
[24].
2.5. Monocyte adhesion assays
a) Static. C57/BL6 male mouse peripheral blood monocytes were
isolated as per the manufacturer’s instructions (EasySep Mouse
Monocyte Isolation Kit, STEMCELL Technologies, catalog# 19861).
Monocytes or human THP-1 cells (ATCC, catalog# TIB-202) were
stained green with PKH67 (Sigma, catalog# PKH67GL-1 KT, St.
Louis, MO, USA), pre-incubated in CX3CL1-Fc (1.4 nmol/L) or saline
(VEH)-containing medium for 30 min and then added to washed
human umbilical vein endothelial cell (HUVECs) (ATCC, catalog#
PCS-100-010) monolayers for 1 h. For LPS stimulation (Sigma,
catalog# LPS25), HUVEC monolayers were pre-treated with 100 ng/
ml LPS for 30 min, while monocytes or human THP-1 cells were
pre-treated with CX3CL1-Fc (1.4 nmol/L) or saline for 30 min beforeMOLECULAR METABOLISM 20 (2019) 89e101  2018 The Authors. Published by Elsevier GmbH. This is an open a
www.molecularmetabolism.comlayering on confluent LPS-stimulated HUVECs. After 1 h incubation,
PFA fixation, washing, DAPI staining and slide mounting occurred.
An Olympus FV1000 Confocal Microscope was used to collect im-
ages of monocytes or THP-1 cells bound to endothelial cells. Data
are presented as % PKH67þ cells over number of endothelial cells.
b) Flow. THP-1 monocytes were labeled with PKH67 (Sigma) then pre-
incubated with CX3CL1-Fc (1.4 nmol/L) or saline (VEH) for 30 min.
Collagen I-coated glass slides plated with HUVECs until 100%
confluency were washed with RPMI 1640 and then assembled into
flow chambers and connected to a parallel flow system for analyses
[25]. The HUVEC monolayer was exposed to a steady shear stress of
1 dyne/cm2 of treated THP-1 cells for 10 min. After flow chamber
disassembly, slides were washed and fixed with 4% para-
formaldehyde for 10 min. Slides were then washed and stained with
DAPI. An Olympus FV1000 Confocal Microscope was used to collect
images of THP-1 cells bound to endothelial cells. Data are presented
as % PKH67þ cells over number of endothelial cells.2.6. In vivo leukocyte adhesion and rolling in live capillaries
a) Murine Dorsal Window Chamber Preparation: Eight week-old C57/
BL6 WT male mice were fitted with a dorsal window chamber. The
mice window chamber model is widely used for microvascular
studies in the unanesthetized state, and the complete surgical
technique is described in detail elsewhere [26,27]. Briefly, the
animal was prepared for chamber implantation by an IP injection of
pentobarbital for anesthesia. Sutures were used to lift the dorsal
skin away from the animal, and one frame of the chamber was
positioned on the animal’s back. A chamber consisted of two
identical titanium frames with a 12 mm circular window. With the
aid of a stereomicroscope, one side of the skin fold was removed
following the outline of the window until only a thin layer of retractor
muscle and the intact subcutaneous skin of the opposing side
remained. The intact skin of the other side was exposed to the
ambient environment. Animals were allowed 2 days for recovery.
Finally, catheters (PE-50) were implanted in the carotid artery and
jugular vein. Catheters were tunneled under the skin, exteriorized at
the dorsal side of the neck, and securely attached to the window
frame. Three to four days after the initial surgery, the microvas-
culature was examined, and only animals passing an established
systemic and microcirculatory inclusion criteria entered the study
[28,29]. For inclusion criteria, mice were considered suitable for the
experiments if: 1) systemic parameters were within normal range.
Namely, heart rate (HR) > 400 beat/min, mean arterial blood
pressure (MAP) > 80 mmHg, systemic hematocrit (Hct) > 45%,
and arterial PO2 pressure > 60 mmHg; and 2) microscopic ex-
amination of the tissue in the chamber observed under x650
magnification did not reveal signs of edema or bleeding. For sys-
temic parameters, MAP and heart rate (HR) were recorded contin-
uously (MP 150, Biopac System).
b) Tourniquet ischemia reperfusion (IR): Ischemia was induced for
one-hour tourniquet clamp occlusion of the tissue in the window
chamber model. Briefly, the periphery of the window was occluded
by pressing a thin flat rubber ring (circular clamp). Mice restrained
in a Plexiglas tube during ischemia [30]. Flow obstruction was
induced by slowly tightening a precision threaded screw fixed to the
side of the intact skin of the window chamber. The rubber ring was
pressed against the intact skin and towards the cover-glass.
Microvascular flow was continuously monitored under trans-
illumination, until it ceased in all feeding and drainingccess article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). 91
Original Articlemicrovessels leading in and out of the clamped area without
compression injury. The chamber was checked during the clamping
period to ensure (no flow) that ischemia was maintained.
c) Experimental Setup: The animals were restrained in a tube and the
protruding window chamber was fixed to the microscopic stage for
trans-illumination (BX51WI, Olympus). Measurements were carried
out using a 40X (LUMPFL-WIR, numerical aperture 0.8, Olympus)
water immersion objective. Detailed mappings were made of the
chamber vasculature so that the same vessels studied at baseline
could be followed throughout the experiment. Six to eight arterioles
and venules were selected in each preparation. Fields of observa-
tion and vessels were chosen for study at locations in the tissue
where the vessels were in sharp focus. Leukocyte-endothelium
interaction was studied in all the vessels included in the study.
d) Microhemodynamics: A video image-shearing method was used to
measure vessel diameter (D) [31]. Changes in arteriolar and venular
diameter from baseline were used as indicators of a change in
vascular tone. Arteriolar and venular centerline velocities were
measured on-line using the photodiode cross-correlation method
(Photo Diode/Velocity Tracker Model 102B, Vista Electronics). The
measured centerline velocity (V) was corrected according to vessel
size to obtain the mean RBC velocity [32]. Blood flow (Q) was
calculated from the measured values as Q ¼ p  V (D/2)2.
e) Functional capillary density (FCD): Capillaries were considered
functional if red blood cells (RBCs) transit through the capillary
segments during a 45 s period. FCD was tabulated from the
capillary lengths with RBC transit in an area comprised of 10
successive microscopic fields (420  320 mm2). FCD (cm-1) is the
total length of RBC-perfused capillaries divided by the area of the
field of view.
f) Leukocyte-endothelium interaction: Leukocytes were labeled by
intravenous injection of Texas Red anti-CD45 antibodies (10 mg,
CalTag, catalog# MCD4517). Fluorescently-labeled leukocytes were
excited and images were captured with a Vivid Standard (XF42 filter,
Omega Filters) using a low light camera (ORCA 9247, Hamamatsu).
Briefly, a straight portion of blood vessels was illuminated for 60 s
and video was recorded (10 frames/s). Leukocytes were counted
during video playback in a 100 mm length segment and categorized
according to their flow behavior as “free-flowing”, “rolling” on the
endothelium, and “immobilized” cells.
g) Tissue viability: Equal volumes of Annexin V (Alexafluor 488 con-
jugate; Molecular Probes) and propidium iodide (PI, 0.2 mg/mL,
Molecular Probes) were mixed, and injected 30 min before visual-
ization by intravital microscopy (8 h after the exchange transfusion).
Microscopic images were obtained with a low light video camera
(ORCA 9247, Hamamatsu). Labeled cells were counted in the skin
fold window and data are given as the average number of fluo-
rescent cells counted in 40 selected visual fields (210  160 mm).
Sebaceous glands and hair follicles excluded from the cell counts
due to their consistently high necrosis and apoptosis rate.2.7. Statistics
Statistical methods were not used to predetermine necessary sample
size, but sample sizes were chosen based on estimates from pilot
experiments and previously published results such that appropriate
statistical tests could yield significant results. Parametric tests were
used that assume normal distribution, which was the case when data
were plotted as frequencies. Variances were tested by Levene’s test
for homogeneity of variance, and variances in the data were not
significantly different. Experiments were not performed in a blinded92 MOLECULAR METABOLISM 20 (2019) 89e101  2018 The Authors. Published by Elsevier GmbH. Tfashion and inclusion/exclusion criteria was not specified at any point.
The results are shown as means  SEM. All statistical analyses were
performed by a one-tailed or two-tailed Student’s t-test or ANOVA, with
Bonferroni posthoc unless otherwise indicated; p < 0.05 was
considered significant. A representative figure for each experiment is
presented without combining of data from different batch experiments,
unless indicated in the figure legend.
2.8. Study approval
Animal protocols were approved by the Institutional Animal Care and
Use Committee (IACUC) at University of California San Diego. All animal
procedures were performed in accordance with the IACUC-approved
protocols and the research guidelines for the use of laboratory ani-
mals of the University of California, San Diego.
3. RESULTS
3.1. CX3CL1-Fc reduces atherosclerotic lesions in a prevention
model of atherosclerosis
In initial studies, we assessed the pharmacokinetics of CX3CL1-Fc in
Ldlr KO mice after a single CX3CL1-Fc IP injection at 30 mg/kg. This
dose was chosen based our previous CX3CL1-Fc treatment studies
[13]. CX3CL1 levels achieved a Cmax ofw3 nmol/L at 3 h, and plasma
levels of 1.85 nmol/L by 72 h (Figure 1A). Using a slightly modified
dosing regimen based on our previous studies demonstrating the anti-
diabetic effects of CX3CL1-Fc [13], we IP injected 30 mg/kg CX3CL1-
Fc twice per week to keep serum levels abovew1.5 nmol/L. Ldlr KO
mice at 8 weeks of age were fed a Western Diet (WD, 40% fat/1.25%
cholesterol) for 4 months and treated with IP saline (VEH) or CX3CL1-Fc
injections (Figure 1B). At sacrifice 24 h after the final injection, total
serum CX3CL1 levels in CX3CL1-Fc mice werew2 nmol/L compared
with VEH-treated mice at 0.14 nmol/L with no change in body weight
or cholesterol (Figure 1CeE). The cholesterol FPLC profiles were
relatively similar between CX3CL1-Fc and VEH-treated groups
(Figure 1F).
CX3CL1-Fc treatment significantly reduced en face aortic lesion area
by 30% (Figure 1G). Analysis of serial sections of the aortic root
demonstrated a comparable 30% decrease in lesion area (Figure 1H)
and necrotic area within the lesions (Figure 1I) in CX3CL1-Fc-treated
Ldlr KO mice compared to VEH-treated controls. Interestingly, the
decrease in necrotic area in CX3CL1-Fc-treated mice was w40%
compared to the 30% decrease in total lesion area, suggesting that
CX3CL1-Fc may play a role in preventing necrosis independent of
lesion size (Figure 1H,I AUC). To further analyze plaque stability, we
evaluated the a-SMA positive area and collagen content in the aortic
root and found a significant increase in the CX3CL1-Fc-treated Ldlr KO
mice compared to controls (Fig. S1A and S1B). Flow cytometry ana-
lyses of aortic wall cell digests showed no change in total macro-
phages, but a reduction in M1-like polarized macrophages (CD86þ)
and T lymphocytes (CD3þ), with no change in M2-like macrophages
(CD206þ) in CX3CL1-Fc-treated mice compared with VEH controls
(Figure 1J-1M). This shows that CX3CL1-Fc confers changes in im-
mune cell population of lesion areas, as well as a quantitative decrease
in lesion size.
In order to rule out potential effects of CX3CL1-Fc on monocyte
development, we placed Ldlr KO mice on a Western Diet for 1 month
during which they were treated with biweekly injections of CX3CL1-Fc
or saline (VEH). We then isolated splenocytes and bone marrow cells
and conducted flow cytometry, which showed no significant difference
in the percentage of CD11bþ Gr-1þ or CD11bþ Gr-1- cell pop-
ulations of CD45þ live cells between both groups (Fig. S2A and S2B).his is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Figure 1: CX3CL1-Fc reduces atherosclerotic lesions in a prevention model of atherosclerosis. (A) Circulating CX3CL1 levels after one injection of CX3CL1-Fc (30 mg/kg) in
Ldlr KO mice. After injection, CX3CL1 levels were rapidly increased with stabilization atw2 nmol/L after 24 h (n ¼ 4). (B) A schematic of prevention study design. CX3CL1-Fc/VEH
treatment was started when mice were provided the high-fat/high-cholesterol Western Diet (WD) for 4 months. (CeF) Serum CX3CL1 and lipid content at sacrifice. (C) CX3CL1-Fc-
treated mice havew14 times more serum CX3CL1 in their blood (n ¼ 7e10). Body weight (D), serum cholesterol (E), FPLC cholesterol profile of Ldlr KO mice after 4 months of
WD treated with CX3CL1-Fc/VEH (n ¼ 13). (G) En face analysis of total aorta. Percent Sudan IV positive staining over total aortic area in Ldlr KO mice treated with CX3CL1-Fc/VEH,
representative images are shown (n ¼ 4e7). Cross-sectional aortic root analyses of lesion size (H) and necrotic area within lesions (I), representative images are shown to the right
(n ¼ 4e7). AUC, area under the curve. A.U., arbitrary unit. (JeM) Flow cytometry analysis of aortic cell digests showed no difference the in percentage of macrophages of
CD45þ Live cells (J). However, there was a decrease in CD86þ M1-like polarized macrophages (K) and no change in CD206þ M2-like polarized macrophages (L) as a percent of
total macrophages (CD64þ CD11bþ) in mice treated with CX3CL1-Fc (n ¼ 9). Also, a decrease in CD3þ T cells (M) as a percent of CD45þ Live cells was observed in aortic cell
digests of CX3CL1-Fc treated mice (n ¼ 9). Data are presented as mean  SEM. #p < 0.05 (one-tailed t-test). For all panels, values are mean  SD. *p < 0.05 and ***p < 0.001.
MOLECULAR METABOLISM 20 (2019) 89e101  2018 The Authors. Published by Elsevier GmbH. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Figure 2: CX3CL1-Fc reduces atherosclerosis in Ldlr KO mice independent of improving glucose tolerance. Under the same scheme as Figure 1 except for use of a high-
cholesterol (1.25%)/low-fat (4.4%) diet, (A) insulin levels are unchanged between CX3CL1-Fc and VEH-treated Ldlr KO mice (n ¼ 8). (B) En face analysis of total aorta. CX3CL1-Fc-
treated Ldlr KO mice had significantly less aortic lesion area on the aortic surface. Representative images are shown below (n ¼ 8). (CeD) Sections of the aortic root show
decreased lesion size (C) and decreased necrotic area (D) in mice treated with CX3CL1-Fc compared to controls visualized as area under the curve. Representative images are
shown (n ¼ 8). (EeG) Serum lipid contents. Total serum cholesterol (E), triglycerides (F) and FPLC cholesterol profile (G) show no difference between CX3CL1-Fc-treated and VEH-
treated mice (n ¼ 8). For all panels, data are presented as mean  SD. *p < 0.05 and **p < 0.01.
Original ArticleWe also found no significant difference in the percentage of
CD11bþ F4/80þ or CD11bþ F4/80- cell populations of CD45þ live
cells between both groups (Fig. S2A and S2B). This suggests that
CX3CL1-Fc did not affect monocyte/macrophage development in the
context of these in vivo studies.
We next sought to determine the impact of inhibiting CX3CL1-mediated
monocyte recruitment on established lesions. Ldlr KO mice were fed a
WD for 4 months and then divided into 3 cohorts: cohort 1 was
sacrificed for the determination of “baseline” atherosclerosis, while
cohorts 2 and 3 were continued on the WD for an additional 4 months.
During these final 4 months, cohort 2 was treated with CX3CL1-Fc and
cohort 3 received VEH (Fig. S3A) with atherosclerosis analyses
following treatment. As expected, both cohorts 2 and 3 had a greater
extent of atherosclerosis than observed for cohort 1, but there were no
differences in body weight, en face aortic lesion size or aortic root
lesions between cohort 2 and 3 at the end of study (Fig. S3BeS3D).
There were also no differences observed between cohort 2 and 3 in
total macrophages, nor in M1-like or M2-like macrophages in carotid
wall digests (Fig. S3EeS3G). T cells were also unchanged in both94 MOLECULAR METABOLISM 20 (2019) 89e101  2018 The Authors. Published by Elsevier GmbH. Tcarotid wall digests and lymph nodes (Fig. S3HeS3I). Finally, under
these conditions, CX3CL1-Fc had no effect on Tissue-Resident
Memory T cell (TRM) populations in the spleen, lymph nodes or ca-
rotid arteries (Fig. S4AeS4B).
3.2. CX3CL1-Fc reduces atherosclerosis in Ldlr KO mice in the
absence of insulin resistance
Insulin resistance and hyperglycemia have been implicated as pro-
atherogenic risk factors [33]. Recently, we reported that chronic
CX3CL1-Fc treatment improves glucose tolerance in obese and insulin
resistant rodent models, raising the question as to whether any of the
anti-atherosclerosis effects of chronic CX3CL1-Fc therapy were
mediated by enhancing insulin action and glycemic control [22]. It has
been previously shown that a high cholesterol (1%)/low fat (4.4%) diet
(HCD) can induce atherosclerosis in Ldlr KO mice without the
concomitant obesity and glucose intolerance that occurs with the WD
[34]. Therefore, to determine whether the anti-atherosclerosis effects
of CX3CL1-Fc were independent of the beneficial effects of CX3CL1-Fc
on glucose tolerance, we followed the same protocol as in Figure 1, buthis is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Figure 3: CX3CL1-Fc administration reduces atherosclerosis after diet switch. (A) A schematic of the diet switch study. CX3CL1-Fc injections began after switch from 4
months of WD to normal chow diet (NCD). (B) Body weight of baseline mice are significantly higher than 8 month mice after diet switch (n ¼ 8e10). (CeF) Serum lipid analyses.
Total serum cholesterol (C) and triglycerides (D) are significantly decreased in mice that are switched from WD to NCD with no differences between CX3CL1-Fc-treated mice and
controls (n ¼ 6e9). FPLC profiles of cholesterol (E) and triglycerides (F) show a decrease in 4 and 8 month diet switch mice with no difference between CX3CL1-Fc and VEH
controls (Data are a pool of serum from 8 mice). (G) En face analysis of total aorta. Aortic lesion area is reduced in CX3CL1-Fc-treated mice compared to controls at 4 and 8 months
after diet switch. Representative images are shown on the right (n ¼ 7e10). (H) Cross-sectional analysis of aortic root area. Aortic root sections shown as area under the curve
have significantly less lesion area in CX3CL1-Fc mice at 4 and 8 months after diet switch (n ¼ 7e12). AUC, area under the curve. A.U., arbitrary unit. In all panels, data are
presented as mean  SD. */& p < 0.05, **/&& p < 0.01, ***/&&& p < 0.001. In (H), * denotes significance between 4M VEH and 4M CX3CL1-Fc, while & denotes significance
between 8M VEH and 8M CX3CL1-Fc.fed mice a HCD instead. Insulin levels were the same in Ldlr KO mice
fed normal chow or HCD diet and after 4 months of CX3CL1-Fc
treatment, insulin levels were w0.8 ng/ml, regardless of CX3CL1-Fc
or VEH treatment (Figure 2A). This serum insulin level is in line with
other reports of normal chow-fed Ldlr KO or C57/Bl6 mice [35,36]. Ldlr
KO mice fed a HCD showed a significant w25% reduction in aortic
lesion area (Figure 2B), with aw40% decrease across the aortic root
(Figure 2C). Necrosis area in the aortic root was significantly reduced
with a concomitant increase in a-SMA positivity in mice treated with
CX3CL1-Fc compared to controls (Figure 2D and Fig. S1B). No change
in collagen was observed between the groups (Fig. S1A). Total plasma
cholesterol (Figure 2D) and triglyceride (Figure 2E) levels were com-
parable between the 2 groups, but the absolute levels were lower than
observed with the WD. In addition, the cholesterol FPLC profiles were
similar between both the CX3CL1-Fc and VEH group under this diet
regiment (Figure 2F). These results show that CX3CL1-Fc can prevent
atherosclerosis independent of glucose intolerance and pronounced
hypercholesterolemia.MOLECULAR METABOLISM 20 (2019) 89e101  2018 The Authors. Published by Elsevier GmbH. This is an open a
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To further understand the effects of the CX3CL1-Fc intervention on
atherosclerosis, a model of atherosclerosis after diet switch was
studied, in which Ldlr KO mice were fed a WD for 4 months then
switched to a normal chow diet (NCD). At the time of diet switch from
WD to NCD, the mice were treated with CX3CL1-Fc or VEH for 4 or 8
additional months (Figure 3A). As expected, baseline mice (Ldlr KO
mice fed a WD for 4 months) showed increased body weight
(Figure 3B) compared with either CX3CL1-Fc or VEH mice at both 4
months and 8 months after the diet switch. The FPLC cholesterol and
triglyceride profiles were not different between CX3CL1-Fc or VEH
groups at either 4 and 8 months, though obviously different than those
of mice at baseline on WD (Figure 3C,D). It is of interest that, after diet
switch, circulating cholesterol and triglyceride levels normalize
(Figure 3E,F). Despite this, atherosclerosis, as assessed by lesion area,
continues to progress, consistent with previous reports (Figure 3G)
[37,38]. In contrast, compared to the 4M and 8M VEH controls,
CX3CL1-Fc treatment led to a significant w25% decrease in lesionccess article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). 95
Figure 4: CX3CL1-Fc reduces monocyte cell adhesion to endothelial monolayers. (A) In vitro THP-1 adhesion assay under flow conditions. THP-1 cells pre-treated with
CX3CL1-Fc are significantly less adherent to a HUVEC monolayer when under a shear stress of 1 dyne/cm2 compared to VEH-treated controls. Representative images are shown
(n ¼ 3). (BeC) Static in vitro THP-1 adhesion assays. CX3CL1-Fc pre-treatment of THP-1 cells leads to reduced adhesion to a HUVEC monolayer under normal (B) and LPS-
stimulated conditions (C). Representative images are shown (n ¼ 3). (DeE) Static in vitro peripheral blood monocyte adhesion assays. Peripheral blood monocytes pre-
treated with CX3CL1-Fc are less adherent to a HUVEC monolayer under normal (D) and LPS-stimulated (E) conditions. Representative images are shown (n ¼ 3). Monocytes
are shown in green and nuclei are labeled with DAPI. Scale bar ¼ 100 mm. Data in both panels are presented as mean  SD. *p < 0.05.
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area after both 4 and 8 months of treatment (Figure 3G). A similar
increase in aortic root lesion area was observed in 4M and 8M VEH-
treated mice (Figure 3H). In contrast, a dramatic inhibition of pro-
gression of lesion formation was observed at the aortic root in CX3CL1-
Fc-treated mice at both 4M and 8M. Absolute lesion areas were equal
to that observed in mice at the 4 month baseline period, prior to
treatment (Figure 3H). Thus, initiating CX3CL1-Fc treatment at the time
of the diet switch completely prevented the subsequent progression of
atherosclerosis lesions at the aortic root and attenuated the continued
progression observed in the aorta. Since the CX3CL1-Fc group
exhibited much less atherosclerosis progression after the diet switch,
this indicates that CX3CL1-Fc caused atheroprotective effects that
were cholesterol independent.
To characterize the quality of immune cell populations, we harvested
cells for flow cytometry analysis from Ldlr KO mice fed a WD for 4
months then switched to NCD after 4 months, while treated with
CX3CL1-Fc or VEH. In carotid cell digests, we observed no difference in
the percentage of macrophages or percentage of T cells in CD45þ live
cells, nor any differences in M1-like or M2-like macrophages as a
percentage of total macrophages (Fig. S5A). Furthermore, in lymph
nodes and splenocytes, there were no differences observed between
the groups in the percentage of T cells of CD45þ live (Fig. S5B and
S5C). This diet-switch study shows that CX3CL1-Fc significantly de-
creases aortic lesion size, consistent with the prevention study results
(Figure 1). However, immune cell populations were not affected,
perhaps due to the greater effect of the lesion size.
3.4. CX3CL1-Fc reduces monocyte adhesion under flow and static
conditions
To assess the ability of CX3CL1-Fc to block monocyte binding to
endothelial cells, we used an in vitro system to measure the binding of
human THP-1 cells to a HUVEC layer under flow and static conditions.
As seen in Figure 4A, THP-1 cells incubated with CX3CL1-Fc for
30 min prior to 1 dyne/cm2 flow over a HUVEC monolayer led to
significantly fewer adhered THP-1 cells. To confirm these results,
static monocyte adhesion assays were conducted in 24-well plates.
Pretreating THP-1 cells for 30 min with CX3CL1-Fc reduced adhesion
to a HUVEC monolayer by 50% (Figure 4B). Prior treatment of HUVECs
with LPS (100 ng/ml for 30 min) led to an increase in THP-1 cell
binding while concomitant pre-treatment with CX3CL1-Fc completely
prevented this effect (Figure 4C). Similar results were observed when
murine peripheral blood monocytes were used instead of THP-1 cells
(Figure 4DeE).
3.5. CX3CL1-Fc prevents in vivo leukocyte adhesion and rolling
To translate our in vitro monocyte adhesion studies to the in vivo
situation, we used a dorsal window chamber model (DWCM) to study
murine microvascular dynamics [39]. This chamber provides a method
to control the blood supply into the ‘windowed’ skin area, allowing
analysis of blood cell dynamics after IR injury. To test the effect of
CX3CL1-Fc administration on leukocyte binding to the stressed vessel
wall, DWCM-fitted wild-type C57/BL6 mice were exposed to local skin
ischemia for 1 h, followed by blood reperfusion and concomitant
intravenous injection of 30 mg/kg CX3CL1-Fc or VEH via the carotid
artery. Leukocytes and other cells within the skin microvasculature
were visualized by microscopy and quantified over 24 h. In CX3CL1-
Fc-treated mice, the number of adherent and rolling leukocytes on
the capillary vascular wall was significantly decreased at 30 min, 2 h
and 24 h after reperfusion compared to VEH-treated controls
(Figure 5AeB). This was accompanied by increased venous blood flow
and functional capillary density (Figure 5CeD). No changes in meanMOLECULAR METABOLISM 20 (2019) 89e101  2018 The Authors. Published by Elsevier GmbH. This is an open a
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24 h measurement was made, fluorescently labeled annexin V anti-
bodies and propidium iodide were injected into the window chambers
of CX3CL1-Fc or VEH treated mice in order to label apoptotic or
necrotic cells, respectively. Confocal microscopy analyses from 40
different fields in the insulted skin area showed that CX3CL1-Fc
treated mice exhibited significantly reduced apoptosis (number of
annexin V labeled cells, Figure 5G) and necrosis (number of propidium
iodide labeled cells, Figure 5H).
4. DISCUSSION
The current studies show that chronic treatment of Ldlr KO mice with a
long acting CX3CL1-Fc fusion protein (and CX3CR1 agonist) led to a
significant decrease in atherosclerotic lesions in the context of both
disease progression and diet switch. This occurred without a change in
plasma cholesterol levels. CX3CL1-Fc interfered with monocyte
binding to HUVEC cells in vitro and reduced leukocyte rolling/adhesion
in murine vessels in vivo. These changes were associated with
decreased aortic wall M1-like macrophages and T cells, which would
be expected to further decrease the chronic inflammatory milieu in the
lesions. These results indicate that treatment with a long-acting
CX3CR1 agonist prevents monocytes from adhering to the endothe-
lial wall, thus, reducing atherosclerosis.
Monocyte/macrophages are the major leukocyte subset in athero-
sclerotic plaques [40] and depletion of these cells reduces athero-
sclerotic lesion area [41]. Many studies have implicated monocyte
adhesion to the endothelium as a necessary step in the development of
atherosclerosis [8,42]. Therefore, inhibiting monocyte-endothelial cell
interactions should be atheroprotective. CX3CL1 is a cell membrane
spanning ligand and the extracellular domain interacts with CX3CR1 on
circulating monocytes to promote monocyte-endothelial cell adhesion.
As well, activation of CX3CR1 can enhance monocyte-endothelial cell
adhesion and transmigration by inducing expression of other adhesion
molecules [43].
Ldlr or ApoE KO mice with either CX3CL1 or CX3CR1 KO exhibit
reduced atherosclerosis and lesion monocytes/macrophages
[16,18,44,45]. Moreover, it has been shown that competitive inhibition
of CX3CR1 by an antagonist reduces the progression of atherosclerosis
in both ApoE and Ldlr KO mice [46]. In the present studies, we utilized
a novel approach by treating mice with a long acting CX3CR1 agonist
rather than an antagonist. Since KOs of CX3CR1 or CX3CL1 are
atheroprotective due to reduced monocyte-endothelial cell in-
teractions, we reasoned that large amounts of extracellular CX3CL1-Fc
would both agonize the CX3CR1 receptor and interfere with the normal
interactions between monocytes and endothelial cells. Agonizing
CX3CR1 avoids monocyte cell death associated with blocking CX3CL1-
CX3CR1 signaling, while the decoy feature prevents monocyte-
endothelial cell adhesion necessary for atherosclerosis [47]. As pre-
dicted, in vitro treatment with CX3CL1-Fc prevented monocyte adhe-
sion to a HUVEC monolayer under normal and pro-inflammatory
conditions. Moreover, using in vivo DWCM studies, we found that
leukocyte adhesion/rolling on the endothelial lining of living mice was
significantly decreased after treatment with CX3CL1-Fc compared with
VEH-treated controls. Importantly, Ldlr KO mice treated with CX3CL1-
Fc showed significantly reduced atherosclerotic lesions in both pre-
vention and diet switch models of atherosclerosis. Since CX3CL1-Fc
treatment can also stimulate CX3CR1 receptor signaling in circu-
lating blood monocytes, our results suggest that circulating monocyte
recruitment to the endothelial wall relies largely on the physical
interaction between CX3CL1 and CX3CR1. Therefore, while the resultsccess article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). 97
Figure 5: CX3CL1-Fc administration prevents in vivo leukocyte adhesion and rolling on the vascular wall. A dorsal window chamber model was used to visualize
leukocytes traveling through capillaries in vivo. (AeB) C57/BL6 male mice treated with CX3CL1-Fc (30 mg/kg) for 30 min prior to 1 h of local ischemia had significantly fewer
leukocytes adhered (A) and rolling (B) along the capillaries of the dorsal skin at 0.5 h, 2 h and 24 h after reperfusion (n ¼ 4). (C) Venous blood flow was significantly increased in
CX3CL1-fc-treated mice compared with VEH after 0.5 h and 2 h after reperfusion (n ¼ 4). (D) Functional capillary density as a measurement by perfused capillaries after ischemia-
reperfusion was significantly increased in CX3CL1-Fc-treated mice compared with controls (n ¼ 4). (EeF) Mean arterial pressure (E) and heart rate (F) in mice treated with
CX3CL1-Fc or VEH (n ¼ 4). (GeH) Tissue apoptosis (G) and necrosis (H) was significantly reduced in CX3CL1-Fc treated mice (n ¼ 4). Data are presented as mean  SD.
*p < 0.05 **p < 0.01 and ***p < 0.001. In (D), # denotes p < 0.05 between 0.5 h and baseline, % denotes p < 0.05 between 2 h and baseline and & notes p < 0.05 between
24 h and 0.5 h after Bonferroni posthoc test.
Original Articlesupport previous data illustrating the role of CX3CR1-CX3CL1 in-
teractions in monocyte adhesion and atherosclerosis progression, they
also provide important new evidence showing that a long acting
CX3CL1 agonist can block monocyte-endothelial interactions and
improve atherosclerosis. It is important to note that since CX3CL1-Fc
treatment is associated with significantly reduced lesion size, this
would mean that absolute number of aortic wall macrophages would
be decreased. The relevance of this to human atherosclerosis is
suggested by the observation that CX3CL1 is expressed in human
carotid artery plaques in all stages of atherosclerosis [17] and that
loss-of-function variants of the human CX3CR1 gene (with decreased
CX3CL1 binding affinity) are associated with reduced CVD [19].
We utilized 3 separate protocols to assess the effects of CX3CL1-Fc
treatment on atherosclerosis. In the mode of prevention (concomi-
tant onset of treatment and WD) and reversion (onset of CX3CL1-Fc
treatment at the time of cholesterol lowering due to the WD to chow
switch), CX3CL1-Fc was highly efficacious at reducing atherosclerosis.
However, with established atherosclerosis (treatment study), CX3CL1-
Fc was without beneficial effects in the context of sustained and98 MOLECULAR METABOLISM 20 (2019) 89e101  2018 The Authors. Published by Elsevier GmbH. Tmarked hypercholesterolemia (Fig. S3). The efficacy of CX3CL1-Fc
treatment may be restricted to conditions whereby ongoing mono-
cyte recruitment is necessary to influence disease status. In this case,
monocyte adhesion may be most important at the beginning and
termination of WD. In the treatment mode, monocytes have already
infiltrated the vessel wall to become foam cells and this may explain
why CX3CL1-Fc was ineffective since its anti-atherosclerosis effects
are cell adhesion-dependent. Indeed, previous studies suggest that the
macrophage contribution to established lesions is due primarily to in
situ proliferation rather than monocyte recruitment [48]. By contrast,
during early atherosclerosis, monocyte recruitment has a more pro-
found role [48]. In the diet switch study, we observed increased
atherosclerosis progression in the VEH mice at 4 and 8 months
compared to baseline. This result has been observed by other groups
[37,38]. Interestingly, significant remodeling occurs soon after the diet
switch, which involves changes in macrophages, T cells and neutro-
phils in the atherosclerotic lesions [37]. This is consistent with our
proposed mechanism that CX3CL1-Fc has anti-atherosclerosis effects
when lesions are cell adhesion-dependent. Consistent with thesehis is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
www.molecularmetabolism.com
observations in mice, regression of atherosclerosis takes a long period
of time after a cholesterol-lowering regimen. There may also be effects
related to T cells but our current study does not explore this. These
current results show that CX3CL1-Fc improves atherosclerosis in a
cholesterol-independent manner, raising the possibility that the use of
a long acting soluble CX3CL1 could provide an additive anti-
atherosclerosis efficacy additive to cholesterol-lowering drugs such
as statins.
Of interest, chronic CX3CL1-Fc administration reduced the necrotic
core area in aortic root cross sections. The magnitude of this effect on
necrotic area wasw10% greater than the effect of CX3CL1-Fc on total
lesion size suggesting that it is not simply due to decreased plaque
formation in CX3CL1-Fc treated mice. In the process of atheroscle-
rosis, early stage fatty streaks can develop into fibroatheroma with a
cell-free, lipid-rich necrotic core. Increased apoptosis of the infiltrated
macrophages and vascular smooth muscle cells contributes to the
expansion of this necrotic core. This feature of atherosclerotic lesions
can cause plaque instability and plaque rupture which is a major
trigger for life-threatening acute coronary events. The effect of
CX3CL1-Fc treatment to increase plaque content of collagen and a-
SMA is consistent with improved plaque stability. Recently, Zhao et al.
have shown that CX3CR1 activation suppresses apoptosis in macro-
phages and vascular smooth muscle cells [49], whereas, CX3CR1
inhibition decreases monocyte survival [46,50]. It is likely that the
proinflammatory immune cells, which propagate within atherosclerotic
areas, facilitate necrosis of cells within these lesions and this is a well-
known contributor to plaque rupture and instability [51]. Our findings
that CX3CL1-Fc treatment leads to decreased apoptosis and necrosis
in the IR model, along with decreased areas of necrosis within the
remaining aortic atherosclerotic lesions, raises the possibility that
treatment with CX3CL1-Fc may lead to stabilization of existing plaques,
as well as prevention of their development. However, it should be
noted that the IR model is different from hypercholesterolemia-induced
insults, and this should be further investigated.
Our previous studies demonstrated that CX3CL1-Fc treatment im-
proves glucose metabolism and insulin sensitivity in high-fat diet-
induced obese mice [22]. In the current study, we have shown that
CX3CL1-Fc reduces atherosclerosis even in cohorts of HCD-fed Ldlr KO
mice that do not have glucose intolerance (Figure 2) [34]. This com-
bination of therapeutic benefits makes CX3CL1-Fc an interesting
candidate for potential treatment of T2DM. Indeed, poor glycemic
control is associated with increased CVD risk [52], and many studies
have shown that high glucose or high fat can promote a pro-
atherogenic state in endothelial cells [53]. CX3CL1-Fc is unique in
that it has a direct beneficial effect on beta cell function, insulin
sensitivity, and atherosclerosis, which could be an advantage over
current treatment modalities. However, since CX3CL1 can lead to
platelet activation and aggregation, the potential for thrombosis should
be considered in future translational studies [54e56]. Thus, using our
approach with a circulating CX3CR1 agonist, one can harness the
beneficial anti-diabetic effects to the atheroprotective effects shown
here and this could provide a clinical advantage.
In summary, treatment of Ldlr KO mice with CX3CL1-Fc interferes with
native CX3CR1-CX3CL1 interactions, leading to reduced lesion im-
mune cell accumulation, less atherosclerotic lesions and decreased
necrotic core area. This occurred in both prevention and diet-switch
models of atherosclerosis. Therefore, it is possible that soluble
CX3CL1 administration is not only protective from early atheroscle-
rosis, but also beneficial for managing late stage atherosclerosis.
Coupled with our earlier results showing the metabolic benefit of
CX3CL1-Fc treatment on glucose homeostasis [22], long acting solubleMOLECULAR METABOLISM 20 (2019) 89e101  2018 The Authors. Published by Elsevier GmbH. This is an open a
www.molecularmetabolism.comCX3CL1-Fc treatment may ultimately find a role in our therapeutic
armamentarium.
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